Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis

Archives of Neurology

Volumn 65, Issue 2, 2008, Pages 236-243

  Di Perri, Carol ^a   Battaglini, Marco ^a   Stromillo, Maria L ^a   Bartolozzi, Maria L ^b   Guidi, Leonello ^b   Federico, Antonio ^a   De Stefano, Nicola ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Hospital of Empoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; WHITE MATTER;

ADULT; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS;

EID: 39049158789     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2007.51     Document Type: Article

References (62)

1. Mcalpine D. The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain. 1961;84:186-203.
2. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120(pt 6):1085-1096.
3. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci. 2002;199(1-2):1-15.
4. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990;300(6725):631-634.
5. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991;29(1):53-62.
6. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60(1):15-19.
7. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121:687-697.
8. Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology. 1999;52(4):839-845.
9. van Walderveen MA, Lycklama ANG, Ader HJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol. 2001;58(1):76-81.
10. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999;52(3):588-594.
11. Filippi M, Inglese M, Rovaris M, et al. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology. 2000;55(7):940-946.
12. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain. 2001;124(pt 12):2540-2549.
13. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2002;23(6):985-988.
14. Rocca MA, Iannucci G, Rovaris M, Comi G, Filippi M. Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions: a diffusion tensor MR study. J Neurol. 2003;250(4):456-460.
15. Lin X, Blumhardt LD, Constantinescu CS. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand. 2003;108(6):401-406.
16. Filippi M, Rovaris M, Rocca MA. Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. Mult Scler. 2004;10(suppl 1):S36-S44.
17. Moore GR. MRI correlates of MS pathologic subtypes. Mult Scler. 2005;11(1):103-105.
18. Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol. 2005;26(2):341-346.
19. Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Polman CH. Cognitive impairment and decline in different MS subtypes. J Neurol Sci. 2006;245(1-2):187-194.
20. Bieniek M, Altmann DR, Davies GR, et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(9):1036-1039.
21. Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology. 2002;58(6):866-872.
22. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707-717.
23. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis: pathology of recurrent lesions. Brain. 1993;116:681-693.
24. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994;117(pt 4):759-765.
25. Lucchinetti C, Bruck W. The pathology of primary progressive multiple sclerosis. Mult Scler. 2004;10(suppl 1):S23-S30.
26. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry. 2005;76(9):1255-1258.
27. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997;41(3):385-391.
28. Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain. 1999;122(pt 7):1261-1270.
29. Charil A, Zijdenbos AP, Taylor J, et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage. 2003;19(3):532-544.
30. Wen W, Sachdev P. The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals. Neuroimage. 2004;22(1):144-154.
31. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke. 2005;36(1):50-55.
32. Enzinger C, Smith S, Fazekas F, et al. Lesion probability maps of white matter hyperintensities in elderly individuals: results of the Austrian stroke prevention study. J Neurol. 2006;253(8):1064-1070.
33. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46(5):747-754.
34. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407-415.
35. De Stefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain. 2006;129(pt 8):2008-2016.
36. Inglese M, Grossman RI, Filippi M. Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution. J Neuroimaging. 2005;15(4)(suppl):22S-29S.
37. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231.
38. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831-835.
39. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911.
40. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444- 1452.
41. Pike GB, Glover GH, Hu BS, Enzmann DR. Pulsed magnetization transfer spinecho MR imaging. J Magn Reson Imaging. 1993;3(3):531-539.
42. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998;19(4):675-683.
43. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(suppl 1):S208-S219.
44. Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000;215(3):824-830.
45. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002;15(1):1-25.
46. Duvernoy HM. The Human Brain: Surface, Blood Supply, and Three-Dimensional Sectional Anatomy. New York, New York: Springer; 1999.
47. Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005;252(suppl 3):iii3-iii9.
48. Wolinsky JS. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol. 2006;98:273-292.
49. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007;61(4):300-306.
50. Vukusic S, Confavreux C. Primary and secondary progressive multiple sclerosis. J Neurol Sci. 2003;206(2):153-155.
51. Wakana S, Jiang H, Nagae-Poetscher LM, van Zijl PC, Mori S. Fiber tract-based atlas of human white matter anatomy. Radiology. 2004;230(1):77-87.
52. Filippi M, Rocca MA. Magnetic resonance imaging techniques to define and monitor tissue damage and repair in multiple sclerosis. J Neurol. 2007;254(suppl 1):I55-I62.
53. Samson RS, Wheeler-Kingshott CA, Symms MR, Tozer DJ, Tofts PS. A simple correction for B1 field errors in magnetization transfer ratio measurements. Magn Reson Imaging. 2006;24(3):255-263.
54. Vrenken H, Geurts JJ, Knol DL, et al. Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. AJNR Am J Neuroradiol. 2006;27(9):2005-2011.
55. Tortorella C, Viti B, Bozzali M, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology. 2000;54(1):186-193.
56. Kalkers NF, Hintzen RQ, van Waesberghe JH, et al. Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. J Neurol Sci. 2001;184(2):155-162.
57. Dehmeshki J, Silver NC, Leary SM, Tofts PS, Thompson AJ, Miller DH. Magnetisation transfer ratio histogram analysis of primary progressive and other multiple sclerosis subgroups. J Neurol Sci. 2001;185(1):11-17.
58. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;60(7):1157-1162.
59. Bookstein FL. "Voxel-based morphometry" should not be used with imperfectly registered images. Neuroimage. 2001;14(6):1454-1462.
60. Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage. 2001;14(6):1238-1243.
61. Davatzikos C. Why voxel-based morphometric analysis should be used with great caution when characterizing group differences. Neuroimage. 2004;23(1):17-20.
62. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31(4):1487-1505.